The DOI matches its Crossref record; 859 of the 859 references it cites were found in a registry or an index.
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Open accessAbstract
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and overexpression of certain RTKs, are critical in creating environments conducive to tumor development. Following their discovery, extensive research has revealed how RTK dysregulation contributes to oncogenesis, with many cancer subtypes showing dependency on aberrant RTK signaling for their proliferation, survival and progression. These findings paved the way for targeted therapies that aim to inhibit crucial biological pathways in cancer. As a result, RTKs have emerged as primary targets in anticancer therapeutic development. Over the past two decades, this has led to the synthesis and clinical validation of numerous small molecule tyrosine kinase inhibitors (TKIs), now effectively utilized in treating various cancer types. In this manuscript we aim to provide a comprehensive understanding of the RTKs in the context of cancer. We explored the various alterations and overexpression of specific receptors across different malignancies, with special attention dedicated to the examination of current RTK inhibitors, highlighting their role as potential targeted therapies. By integrating the latest research findings and clinical evidence, we seek to elucidate the pivotal role of RTKs in cancer biology and the therapeutic efficacy of RTK inhibition with promising treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–600 of 859
Li, D., Chi, Y., Chen, X., Ge, M., Zhang, Y., Guo, Z., Wang, J., Chen, J., Zhang, J., Cheng, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2950 · Cited by 123
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.007 · Cited by 123
Herrmann, J. L., Menter, D. G., Hamada, J., Marchetti, D., Nakajima, M., & Nicolson, G. L. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.11.1205 · Cited by 122
p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
Huang, S., Benavente, S., Armstrong, E. A., Li, C., Wheeler, D. L., & Harari, P. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0128 · Cited by 122
Chhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 122
The role of the c-Met pathway in lung cancer and the potential for targeted therapy
Sattler, M., Hasina, R., Reddy, M. M., Gangadhar, T. C., & Salgia, R. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011408636 · Cited by 121
IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression
Jing, N., Wang, Y., Yang, J. B., & Stark, G. R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714102115 · Cited by 121
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
Gendarme, S., Bylicki, O., Chouaid, C., & Guisier, F. (2022) · Current Oncology · doi:10.3390/curroncol29020057 · Cited by 121
GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential
Mulligan, L. M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01873 · Cited by 120
D’Angelo, A., Sobhani, N., Chapman, R., Bagby, S., Bortoletti, C., Traversini, M., Ferrari, K., Voltolini, L., Darlow, J., & Roviello, G. (2020) · Cancers · doi:10.3390/cancers12113293 · Cited by 120
Quilliam, L. A., Castro, A. F., Rogers-Graham, K. S., Martin, C. B., Der, C. J., & Bi, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23850 · Cited by 119
Giuliano, M., Hu, H., Wang, Y.-C., Fu, X., Nardone, A., Herrera, S., Mao, S., Contreras, A., Gutiérrez, C., Wang, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2728 · Cited by 118
Wang, M.-H., Lee, W., Luo, Y., Weis, M. T., & Yao, H. (2007) · The Journal of Pathology · doi:10.1002/path.2245 · Cited by 118
Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene.
Iyer, A., Kmiecik, T. E., Park, M., Daar, I. O., Blair, D. G., Dunn, K., Sutrave, P., Ihle, J. N., Bodescot, M., & Woude, G. V. (1990) · PubMed · Cited by 118
RET signaling pathway and RET inhibitors in human cancer
Regua, A. T., Najjar, M. K., & Lo, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.932353 · Cited by 118
Weiss, J. B., Xue, C., Benice, T. S., Xue, L., Morris, S. W., & Raber, J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.024 · Cited by 117
Ryks: new partners for Wnts in the developing and regenerating nervous system
Fradkin, L. G., Dura, J., & Noordermeer, J. N. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.005 · Cited by 117
Cross talk of tyrosine kinases with the DNA damage signaling pathways
Mahajan, K. N., & Mahajan, N. P. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1166 · Cited by 117
Azuma, K., Kawahara, A., Sonoda, K., Nakashima, K., Tashiro, K., Watari, K., Izumi, H., Kage, M., Kuwano, M., Ono, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1866 · Cited by 117
EGFR G796D mutation mediates resistance to osimertinib
Zheng, D., Hu, M., Bai, Y., Zhu, X., Lu, X., Wu, C., Wang, J., Liu, L., Wang, Z., Ni, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17913 · Cited by 117
Chen, L., Jiang, Y., Wu, S., Wu, J., Di, G., Liu, G., Yu, K., Fan, L., Li, J., Hou, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4313 · Cited by 117
Mercher, T., Wernig, G., Moore, S. A., Levine, R. L., Gu, T.-L., Fröhling, S., Cullen, D., Polakiewicz, R. D., Bernard, O., Boggon, T. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-014712 · Cited by 116
The EGF receptor: structure, regulation and potential role in malignancy.
Thompson, D. M., & Gill, G. N. (1985) · PubMed · Cited by 116
Jabbour, E. J., Deininger, M. W., & Hochhaus, A. (2010) · Leukemia · doi:10.1038/leu.2010.215 · Cited by 115
Grb2, a Double-Edged Sword of Receptor Tyrosine Kinase Signaling
Belov, A. A., & Mohammadi, M. (2012) · Science Signaling · doi:10.1126/scisignal.2003576 · Cited by 114
Dai, J., Qu, T., Yin, D., Cui, Y., Zhang, C., Zhang, E., & Guo, R. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05840-x · Cited by 114
Ma, F., Yan, M., Li, W., Ouyang, Q., Tong, Z., Teng, Y., Wang, Y., Wang, S., Geng, C., Luo, T., et al. (2023) · BMJ · doi:10.1136/bmj-2023-076065 · Cited by 114
Tyrosine 981, a Novel Ret Autophosphorylation Site, Binds c-Src to Mediate Neuronal Survival
Encinas, M., Crowder, R. J., Milbrandt, J., & Johnson, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400505200 · Cited by 113
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
André, F., & Cortés, J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3301-y · Cited by 113
Borghaei, H., de Marinis, F., Dumoulin, D. W., Reynolds, C. H., Theelen, W. S. M. E., Percent, I. J., Calderón, V. G., Johnson, M. L., Madroszyk, A., Garon, E. B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.004 · Cited by 113
Receptor tyrosine kinases: biological functions and anticancer targeted therapy
Zhang, N., & Li, Y. (2023) · MedComm · doi:10.1002/mco2.446 · Cited by 112
Resistance to Molecularly Targeted Therapies in Melanoma
Patel, M., Eckburg, A., Gantiwala, S., Hart, Z., Dein, J., Lam, K., & Puri, N. (2021) · Cancers · doi:10.3390/cancers13051115 · Cited by 111
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia
Xiang, Z., Zhao, Y., Mitaksov, V., Fremont, D. H., Kasai, Y., Molitoris, A., Ries, R. E., Miner, T. L., McLellan, M. D., DiPersio, J. F., et al. (2007) · Blood · doi:10.1182/blood-2007-05-090308 · Cited by 110
Teramo, A., Gattazzo, C., Passeri, F., Liço, A., Tasca, G., Cabrelle, A., Martini, V., Frezzato, F., Trimarco, V., Ave, E., et al. (2013) · Blood · doi:10.1182/blood-2012-07-441378 · Cited by 110
The Insulin Receptor: A New Target for Cancer Therapy
Malaguarnera, R., & Belfiore, A. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00093 · Cited by 110
Iwashita, T., Asai, N., Murakami, H., Matsuyama, M., & Takahashi, M. (1996) · PubMed · Cited by 110
Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
Zhao, Y., Zhang, D., Guo, Y., Lü, B., Zhao, Z. J., Xu, X., & Chen, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.680834 · Cited by 110
MEN2A-RET-induced cellular transformation by activation of STAT3
Schuringa, J. J., Wojtachnio, K., Hagens, W. I., Vellenga, E., Buys, C. H. C. M., Hofstra, R. M. W., & Kruijer, W. (2001) · Oncogene · doi:10.1038/sj.onc.1204715 · Cited by 109
Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S., Bai, Y., Li, J., Fang, B., Koomen, J. M., Rawal, B., Fisher, K. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1559 · Cited by 109
Targeting EGFR in Lung Cancer: Current Standards and Developments
Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108
Patani, H., Bunney, T., Thiyagarajan, N., Norman, R., Ogg, D., Breed, J., Ashford, P., Potterton, A., Edwards, M., Williams, S. V., et al. (2016) · OncoTarget · doi:10.18632/oncotarget.8132 · Cited by 108
Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 108
Maggiora, P. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00250-7 · Cited by 107
Identification of RET Autophosphorylation Sites by Mass Spectrometry
Kawamoto, Y., Takeda, K., Okuno, Y., Yamakawa, Y., Ito, Y., Taguchi, R., Kato, M., Suzuki, H., Takahashi, M., & Nakashima, I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312600200 · Cited by 107
Lee, H. K., Chauhan, S. K., Kay, E., & Dana, R. (2011) · Blood · doi:10.1182/blood-2010-09-306928 · Cited by 107
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
Zheng, G., Tseng, L., Chen, G., Haley, L. M., Illei, P. B., Gocke, C. D., Eshleman, J. R., & Lin, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1811-y · Cited by 107
Hypoxia-driven intratumor heterogeneity and immune evasion
Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaïb, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 107
Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state
Lin, C., Suen, K. M., Jeffrey, P.-A., Wieteska, Ł., Lidster, J. A., Bao, P., Curd, A., Stainthorp, A. K., Seiler, C., Koss, H., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.005 · Cited by 107
The Wnt Receptor Ryk Plays a Role in Mammalian Planar Cell Polarity Signaling
Macheda, M. L., Sun, W. W., Kugathasan, K., Hogan, B. M., Bower, N. I., Halford, M. M., Zhang, Y. F., Jacques, B. E., Lieschke, G. J., Dabdoub, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.362681 · Cited by 106
Schirripa, M., Biason, P., Lonardi, S., Pella, N., Pino, M. S., Urbano, F., Antoniotti, C., Cremolini, C., Corallo, S., Pietrantonio, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0311 · Cited by 105
Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin
McDonell, L. M., Kernohan, K. D., Boycott, K. M., & Sawyer, S. L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv254 · Cited by 104
Baumgart, A., Seidl, S., Vlachou, P., Michel, L., Mitova, N., Schatz, N., Specht, K., Koch, I., Schuster, T., Grundler, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3763 · Cited by 104
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
Medves, S., & Demoulin, J. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01415.x · Cited by 104
Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas
Moon (2010) · Oncology Reports · doi:10.3892/or_00000861 · Cited by 104
Lu, J., Li, J., Lin, Z., Li, H., Lou, L., Ding, W., Ouyang, S., Wu, Y., Wen, Y., Chen, X., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216205 · Cited by 104
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Loriaux, M., Levine, R. L., Tyner, J. W., Fröhling, S., Scholl, C., Stoffregen, E. P., Wernig, G., Erickson, H., Eide, C. A., Berger, R., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101394 · Cited by 103
Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines
Ruhe, J. E., Streit, S., Hart, S., Wong, C., Specht, K., Knyazev, P. G., Knyazeva, T., Tay, L. S., Loo, H. L., Foo, P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2703 · Cited by 102
Falco, V. D., Buonocore, P., Muthu, M., Torregrossa, L., Basolo, F., Billaud, M., Gozgit, J. M., Carlomagno, F., & Santoro, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2672 · Cited by 102
van der Wekken, A. J., Saber, A., Hiltermann, T. J. N., Kok, K., van den -->Berg, A., & Groen, H. J. M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.024 · Cited by 102
Han, W., Shi, L., Ren, L., Zhou, L., Li, T., Qiao, Y., & Wang, H. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0019-4 · Cited by 102
Wang, M., Fan, Y., Sun, M., Wang, Y., Zhao, Y., Jin, B., Hu, Y., Han, Z., Song, X., Liu, A., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00379-x · Cited by 102
FLT4/VEGFR3and Milroy Disease: Novel Mutations, a Review of Published Variants and Database Update
Gordon, K. D., Spiden, S. L., Connell, F., Brice, G. W., Cottrell, S., Short, J. P., Taylor, R., Jeffery, S., Mortimer, P. S., Mansour, S., et al. (2012) · Human Mutation · doi:10.1002/humu.22223 · Cited by 101
Campochiaro, P. A., Sophie, R., Tolentino, M., Miller, D. M., Browning, D. J., Boyer, D. S., Heier, J. S., Gambino, L., Withers, B., Brigell, M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.09.023 · Cited by 100
Percy, M. J., Scott, L. M., Erber, W. N., Harrison, C. N., Reilly, J. T., Jones, F. G. C., Green, A. R., & McMullin, M. F. (2007) · Haematologica · doi:10.3324/haematol.11643 · Cited by 100
Drug resistance profiles of mutations in the RET kinase domain
Liu, X., Shen, T., Mooers, B. H. M., Hilberg, F., & Wu, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14395 · Cited by 100
Suh, C. H., Park, H. S., Kim, K. W., Pyo, J., Hatabu, H., & Nishino, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.032 · Cited by 100
Liu, H., Zhang, B., & Sun, Z. (2020) · 癌症:英文版 · doi:10.1002/cac2.12005 · Cited by 100
Cardiotoxic effects of angiogenesis inhibitors
Dobbin, S. J. H., Petrie, M. C., Myles, R. C., Touyz, R. M., & Lang, N. N. (2021) · Clinical Science · doi:10.1042/cs20200305 · Cited by 100
Shedding of Discoidin Domain Receptor 1 by Membrane-type Matrix Metalloproteinases
Fu, H.-L., Sohail, A., Valiathan, R. R., Wasinski, B. D., Kumarasiri, M., Mahasenan, K. V., Bernardo, M. M., Tokmina‐Roszyk, D., Fields, G. B., Mobashery, S., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.409599 · Cited by 99
The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
Smart, S. K., Vasileiadi, E., Wang, X., DeRyckere, D., & Graham, D. K. (2018) · Cancers · doi:10.3390/cancers10120474 · Cited by 99
Mudduluru, G., & Allgayer, H. (2008) · Bioscience Reports · doi:10.1042/bsr20080046 · Cited by 98
Mineur, P., Colige, A., Deroanne, C., Dubail, J., Kesteloot, F., Habraken, Y., Noël, A., Vöö, S. A., Waltenberger, J. L., Lapiere, C. M., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703052 · Cited by 98
Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.112 · Cited by 98
Targeting Tie2 in the Tumor Microenvironment: From Angiogenesis to Dissemination
Duran, C. L., Borriello, L., Karagiannis, G. S., Entenberg, D. R., Oktay, M. H., & Condeelis, J. S. (2021) · Cancers · doi:10.3390/cancers13225730 · Cited by 98
Suh, Y., Jo, S., Lee, H., & Lee, C. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2808 · Cited by 97
Shah, R. B., Ghosh, D., & Elder, J. T. (2006) · The Prostate · doi:10.1002/pros.20460 · Cited by 97
PTK7 Faces the Wnt in Development and Disease
Berger, H., Wodarz, A., & Borchers, A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00031 · Cited by 97
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Veluswamy, R., Mack, P. C., Houldsworth, J., Elkhouly, E., & Hirsch, F. R. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.02.002 · Cited by 96
Qin, A., Johnson, A., Ross, J. S., Miller, V. A., Ali, S. M., Schrock, A. B., & Gadgeel, S. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.014 · Cited by 96
Lü, S., Zhou, J., Jian, H., Wu, L., Cheng, Y., Fan, Y., Fang, J., Chen, G., Zhang, Z., Lv, D., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00183-2 · Cited by 96
Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer
Facchinetti, F., Hollebecque, A., Brayé, F., Vasseur, D., Pradat, Y., Bahleda, R., Pobel, C., Bigot, L., Déas, O., Arango, J. D. F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1441 · Cited by 96
Kong, Y., Si, L., Li, Y., Wu, X., Xu, X., Dai, J., Tang, H., Ma, M., Chi, Z., Sheng, X., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1110 · Cited by 95
Weisberg, E., Wright, R. D., Jiang, J., Ray, A., Moreno, D., Manley, P. W., Fabbro, D., Hall–Meyers, E., Catley, L., Podar, K., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.017 · Cited by 95
Rudolph, M., Anzeneder, T., Schulz, A., Beckmann, G., Byrne, A. T., Jeffers, M., Peña, C. E., Politz, O., Köchert, K., Vonk, R., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2626-1 · Cited by 95
Wang, M., Zhou, Y. ‐., & Chen, Y. ‐. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2002.01177.x · Cited by 94
Proteinuria and hypertension with tyrosine kinase inhibitors
Kandula, P., & Agarwal, R. (2011) · Kidney International · doi:10.1038/ki.2011.288 · Cited by 94
Mo, E. S., Cheng, Q., Reshetnyak, A. V., Schlessinger, J., & Nicoli, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710254114 · Cited by 94
Wu, J., Jiang, Z., Liu, Z., Yang, B., Yang, H., Tang, J., Wang, K., Liu, Y., Wang, H., Fu, P., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02708-3 · Cited by 94
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia
Gaikwad, A. S., Rye, C. L., Devidas, M., Heerema, N. A., Carroll, A. J., Izraeli, S., Plon, S. E., Basso, G., Pession, A., & Rabin, K. R. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07552.x · Cited by 93
Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells
Choudhury, A., Derkow, K., Daneshmanesh, A. H., Mikaelsson, E., Kiaii, S., Kokhaei, P., Österborg, A., & Mellstedt, H. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08362.x · Cited by 92
Interferon Regulatory Factors in Hematopoietic Cell Differentiation and Immune Regulation
Battistini, A. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2009.0030 · Cited by 92
Watson, S. S., Dane, M. A., Chin, K., Tatárová, Z., Liu, M., Liby, T. A., Thompson, W., Smith, R. L., Nederlof, M. A., Bucher, E., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.02.001 · Cited by 91
Boye, E., Jinnin, M., & Olsen, B. R. (2009) · Journal of Craniofacial Surgery · doi:10.1097/scs.0b013e318193d6c1 · Cited by 90
ROS1 fusions in Chinese patients with non-small-cell lung cancer
Cai, W., Li, X., Su, C., Fan, L., Zheng, L.-M., Fei, K., Zhou, C., Manegold, C., & Schmid‐Bindert, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt071 · Cited by 90
Gaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89
Harries, L. W., Perry, J. R. B., McCullagh, P. J., & Crundwell, M. C. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-315 · Cited by 89
Diekstra, M. H. M., Swen, J. J., Boven, E., Castellano, D., Gelderblom, H. A. J., Mathijssen, R. H. J., Rodríguez‐Antona, C., García-Donás, J., Rini, B. I., & Guchelaar, H. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.018 · Cited by 89
The Eph/Ephrin family in cancer metastasis: communication at the service of invasion
Kandouz, M. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9352-1 · Cited by 89
Lin, X., Ye, R., Li, Z., Zhang, B., Huang, Y., Du, J., Wang, B., Meng, H., Xian, H., Zhang, X., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100908 · Cited by 89
Endocrine side effects of broad-acting kinase inhibitors
Lodish, M. B., & Stratakis, C. A. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0082 · Cited by 88
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Politi, K. A., Fan, P., Shen, R., Zakowski, M. F., & VARMUS, H. E. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.003681 · Cited by 88
Banno, E., Togashi, Y., Nakamura, Y., Chiba, M., Kobayashi, Y., Hayashi, H., Terashima, M., de Velasco, M. A., Sakai, K., Fujita, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12980 · Cited by 87
STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer
Chen, Y., Wang, J., Wang, X., Liu, X., Li, H., Lv, Q., Zhu, J., Wei, B., & Tang, Y. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.1.40 · Cited by 87
ROR-Family Receptor Tyrosine Kinases
Stricker, S., Rauschenberger, V., & Schambony, A. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.09.003 · Cited by 87
Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
Cabanillas, M. E., Hu, M. I.-N., Durand, J., & Busaidy, N. L. (2011) · Journal of Thyroid Research · doi:10.4061/2011/985780 · Cited by 86
FGFR1 Mutations in Rosette-Forming Glioneuronal Tumors of the Fourth Ventricle
Gessi, M., Moneim, Y. A., Hammes, J., Goschzik, T., Scholz, M., Denkhaus, D., Waha, A., & Pietsch, T. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000080 · Cited by 86
Mutations in the signal transducer and activator of transcription family of genes in cancer
Shahmarvand, N., Nagy, A., Shahryari, J., & Ohgami, R. S. (2018) · Cancer Science · doi:10.1111/cas.13525 · Cited by 86
Origin and Molecular Evolution of Receptor Tyrosine Kinases with Immunoglobulin-Like Domains
Grassot, J., Gouy, M., Perrière, G., & Mouchiroud, G. (2006) · Molecular Biology and Evolution · doi:10.1093/molbev/msk007 · Cited by 85
STAT signaling in the pathogenesis and treatment of myeloid malignancies
Bar‐Natan, M., Nelson, E. A., Xiang, M. H., & Frank, D. A. (2012) · JAK-STAT · doi:10.4161/jkst.20006 · Cited by 85
Lander, R. M., & Petersen, C. P. (2016) · eLife · doi:10.7554/elife.12850 · Cited by 85
Cell and Molecular Biology of Epidermal Growth Factor Receptor
Ceresa, B. P., & Peterson, J. L. (2014) · International review of cytology · doi:10.1016/b978-0-12-800177-6.00005-0 · Cited by 85
The role of RICTOR downstream of receptor tyrosine kinase in cancers
Jebali, A., & Dumaz, N. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0794-0 · Cited by 85
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
Ghosh, A. P., Marshall, C. B., Coric, T., Shim, E., Kirkman, R. L., Ballestas, M. E., Ikura, M., Bjornsti, M., & Sudarshan, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4963 · Cited by 84
The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer
Zhu, X., & Zhou, W. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00159 · Cited by 84
Regulation of HGF and HGFR gene expression
Zarnegar, R. (1995) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-9070-0_3 · Cited by 83
Liu, L., Yu, X.-Z., Li, T.-S., Song, L.-X., Chen, P.-L., Suo, T.-L., Li, Y.-H., Wang, S., Chen, Y., Ren, Y.-M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2106 · Cited by 83
Drakas, R. A., Tu, X., & Baserga, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403328101 · Cited by 82
Kiyoi, H., Yamaji, S., Kojima, S., & Naoe, T. (2007) · Leukemia · doi:10.1038/sj.leu.2404527 · Cited by 82
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
Wei, Q., Chen, L., Sheng, L., Nordgren, H., Wester, K., & Carlsson, J. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.3.493 · Cited by 81
Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery
Rosenkranz, A. A., & Slastnikova, T. A. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920090011 · Cited by 81
Williams, J. A., Sans, M. D., Tashiro, M., Schäfer, C., Bragado, M. J., & Dâbrowski, A. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.910606.x · Cited by 80
Velghe, A. I., Cauwenberghe, S. V., Polyansky, A. A., Chand, D., Montano‐Almendras, C. P., Charni, S., Hallberg, B., Essaghir, A., & Demoulin, J. (2013) · Oncogene · doi:10.1038/onc.2013.218 · Cited by 80
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
Adelaiye-Ogala, R. M., Budka, J. A., Damayanti, N. P., Arrington, J. V., Ferris, M. W., Hsu, C.-C., Chintala, S., Orillion, A. R., Miles, K. M., Shen, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0899 · Cited by 80
Peghini, P. L., Iwamoto, M., Raffeld, M. A., Chen, Y., Goebel, S. U., Serrano, J., & Jensen, R. T. (2002) · PubMed · Cited by 79
Serum Levels of Hepatocyte Growth Factor in Patients with Breast Cancer
Sheen‐Chen, S., Liu, Y., Eng, H.-L., & Chou, F. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0340 · Cited by 79
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Ip, C. K. M., Ng, P. K., Jeong, K. J., Shao, S. H., Ju, Z., Leonard, P. G., Hua, X., Vellano, C. P., Woessner, R. D., Sahni, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06949-w · Cited by 79
Structural Mechanisms of PTEN RegulationPreprint
Masson, G. R., & Williams, R. L. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036152 · Cited by 79
RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer
Mahato, A. K., & Sidorova, Y. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197108 · Cited by 79
Uncovering the pathogenesis of large granular lymphocytic leukemia—novel STAT3 and STAT5b mutations
Rajala, H. L. M., Porkka, K., Maciejewski, J. P., Loughran, T. P., & Mustjoki, S. M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.882105 · Cited by 78
Yau, T. C. C., Lencioni, R. A., Sukeepaisarnjaroen, W., Chao, Y., Yen, C.-J., Lausoontornsiri, W., Chen, P., Sanpajit, T., Camp, A., Cox, D. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1789 · Cited by 78
Imamura, T. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00265 · Cited by 77
Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
Ji, C., Zhang, L., Cheng, Y., Patel, R., Wu, H., Zhang, Y., Wang, M., Ji, S., Belani, C. P., Yang, J., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28162 · Cited by 77
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
Lee‐Sherick, A. B., Jacobsen, K. M., Henry, C. J., Huey, M. G., Parker, R. E., Page, L. S., Hill, A. A., Wang, X., Frye, S. V., Earp, H. S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97941 · Cited by 77
Lei, T., Xu, T., Zhang, N., Zou, X., Kong, Z., Wei, C., & Wang, Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106668 · Cited by 77
KRAS in NSCLC: State of the Art and Future Perspectives
Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76
Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.
Rosty, C., Aubriot‐Lorton, M., Cappellen, D., Bourdin, J., Cartier, I., Thiery, J. P., Sastre‐Garau, X., & Radvanyi, F. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-15 · Cited by 76
Davies, B. R., Guan, N., Logié, A., Crafter, C., Hanson, L. L., Jacobs, V. N., James, N. H., Dudley, P., Jacques, K., Ladd, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0230 · Cited by 76
Mechanism for the activation of the anaplastic lymphoma kinase receptor
Reshetnyak, A. V., Rossi, P., Myasnikov, A. G., Sowaileh, M. F., Mohanty, J., Nourse, A., Miller, D. J., Lax, I., Schlessinger, J., & Kalodimos, C. G. (2021) · Nature · doi:10.1038/s41586-021-04140-8 · Cited by 76
Liu, W., Wang, L., Zhou, F.-M., Liu, S., Wang, W., Zhao, E., Yao, Q.-J., Li, W., Zhao, Y., Shi, Z., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100987 · Cited by 76
Ohgami, R. S., Ma, L., Merker, J. D., Martinez, B., Zehnder, J. L., & Arber, D. A. (2013) · Leukemia · doi:10.1038/leu.2013.104 · Cited by 75
Poudel, B., Lee, Y.-M., & Kim, D. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv005 · Cited by 75
Blalock, W. L., Pearce, M., Steelman, L. S., Franklin, R. A., McCarthy, S. A., Cherwinski, H. M., McMahon, M., & McCubrey, J. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203337 · Cited by 75
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
Ghiaur, G., & Levis, M. J. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.005 · Cited by 75
Self-citationMERTK mutation update in inherited retinal diseases
Audo, I. S., Mohand‐Saïd, S., Boulanger-Scemama, É., Zanlonghi, X., Condroyer, C., Démontant, V., Boyard, F., Antonio, A., Méjécase, C., Shamieh, S. E., et al. (2018) · Human Mutation · doi:10.1002/humu.23431 · Cited by 75
Regulation of JAK3 expression and activation in human B cells and B cell malignancies
Tortolani, P. J., Lal, B. K., Riva, A., Johnston, J. A., Chen, Y. Q., Reaman, G. H., Beckwith, M., Longo, D., Ortaldo, J. R., Bhatia, K., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.11.5220 · Cited by 74
Lisabeth, E. M., Fernandez, C., & Pasquale, E. B. (2012) · Biochemistry · doi:10.1021/bi2014079 · Cited by 74
Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
Cruickshanks, N. A., Zhang, Y., Yuan, F., Pahuski, M., Gibert, M. K., & Abounader, R. (2017) · Cancers · doi:10.3390/cancers9070087 · Cited by 74
Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer
Henriet, E., Sala, M., Hammoud, A. A., Tuariihionoa, A., Martino, J. S. D., Ros, M., & Saltel, F. (2018) · Cell Adhesion & Migration · doi:10.1080/19336918.2018.1465156 · Cited by 74
RET receptor signaling: Function in development, metabolic disease, and cancer
Takahashi, M. (2022) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.98.008 · Cited by 73
Lee, T., Jeong, E., Kim, S. Y., Kim, H.-R., & Kim, C. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29320 · Cited by 72
The Eph family: a multitude of receptors that mediate cell recognition signals
Zisch, A. H., & Pasquale, E. B. (1997) · Cell and Tissue Research · doi:10.1007/s004410050926 · Cited by 72
A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET Mutations
Iwashita, T., Murakami, H., Kurokawa, K., Kawai, K., Miyauchi, A., Futami, H., Qiao, S., Ichihara, M., & Takahashi, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2227 · Cited by 72
Mazot, P., Cazes, A., Boutterin, M., Figueiredo, A. L., Raynal, V., Combaret, V., Hallberg, B., Palmer, R. H., Delattre, O., Janoueix‐Lerosey, I., et al. (2011) · Oncogene · doi:10.1038/onc.2010.595 · Cited by 71
Isolation of Human Colon Stem Cells Using Surface Expression of PTK7
Jung, P., Sommer, C., Barriga, F. M., Buczacki, S. J. A., Hernando‐Momblona, X., Sevillano, M., Duran‐Frigola, M., Aloy, P., Selbach, M., Winton, D. J., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.10.003 · Cited by 71
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera
Schnittger, S., Bacher, U., Haferlach, C., Geer, T., Muller, P., Mittermüller, J., Petrides, P. E., Schlag, R., Sandner, R., Selbach, J., et al. (2009) · Haematologica · doi:10.3324/haematol.13223 · Cited by 71
Xu, W., Zheng, X., Pang, X., Zhang, Z., & Zhang, Q. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.10.018 · Cited by 70
Cutsem, E. V., Yoshino, T., Lenz, H., Lonardi, S., Falcone, A., Limón, M. L., Saunders, M. P., Sobrero, A. F., Park, Y. S., Ferreiro, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy241 · Cited by 70
Omar, N. E., Soliman, A. I. F., Eshra, M. R., Saeed, T., Hamad, A., & Abou‐Ali, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100315 · Cited by 70
Raghunath, M., Patti, R., Bannerman, P. G. C., Lee, C. M., Baker, S. J., Sutton, L. N., Phillips∥, P. C., & Reddy, C. D. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00048-6 · Cited by 69
Gärtner, S., Gunesch, A., Knyazeva, T., Wolf, P., Högel, B., EIERMANN, W., Ullrich, A., Knyazev, P. G., & Ataseven, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084472 · Cited by 69
RET gene is a major risk factor for Hirschsprung’s disease: a meta-analysis
Tomuschat, C., & Puri, P. (2015) · Pediatric Surgery International · doi:10.1007/s00383-015-3731-y · Cited by 68
Dell, S., Peters, S., ̈ther, P. M., Kociok, N., & Joussen, A. M. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1071 · Cited by 68
Haan, C., Behrmann, I., & Haan, S. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01018.x · Cited by 68
Hubbard, S. R., & Gnanasambandan, K. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.02.034 · Cited by 68
Effects of Cancer-Associated EPHA3 Mutations on Lung Cancer
Zhuang, G., Song, W., Amato, K. R., Hwang, Y., Lee, K., Boothby, M. R., Ye, F., Guo, Y., Shyr, Y., Lin, L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs297 · Cited by 68
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
Re, M. D., Rofi, E., Restante, G., Crucitta, S., Arrigoni, E., Fogli, S., Maïo, M. D., Petrini, I., & Danesi, R. (2017) · Oncotarget · doi:10.18632/oncotarget.23553 · Cited by 68
Chen, Y., Chen, L., Yu, J., Ghia, E. M., Choi, M. Y., Zhang, L., Zhang, S., Sánchez‐López, E., Widhopf, G. F., Messer, K. S., et al. (2019) · Blood · doi:10.1182/blood.2019001366 · Cited by 68
Hsu, M.-C., Pan, M.-R., & Hung, W.-C. (2019) · Cells · doi:10.3390/cells8030270 · Cited by 67
Li, S., Songyang, Z., Vincent, S. J. F., Zwahlen, C., Wiley, S. E., Cantley, L. C., Kay, L. E., Forman-Kay, J. D., & Pawson, T. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7204 · Cited by 67
Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword?
Godinas, L., Guignabert, C., Seferian, A., Perros, F., Bergot, E., Sibille, Y., Humbert, M. J. C., & Montani, D. (2013) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0033-1356494 · Cited by 67
Matsushita, C., Tamagaki, H., Miyazawa, Y., Aimoto, S., Smith, S. O., & Sato, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215207110 · Cited by 67
Romaniello, D., Marrocco, I., Nataraj, N. B., Ferrer, I., Garcia, D. D., Vaknin, I., Oren, R., Lindzen, M., Ghosh, S., Kreitman, M., et al. (2020) · Cancers · doi:10.3390/cancers12092394 · Cited by 67
ROS receptor tyrosine kinase: a new potential target for anticancer drugs
El-Deeb, I. M., Yoo, K. H., & Lee, S. H. (2010) · Medicinal Research Reviews · doi:10.1002/med.20206 · Cited by 66
The role of muscle‐specific tyrosine kinase ( MuSK ) and mystery of MuSK myasthenia gravis
Koneczny, I., Cossins, J., & Vincent, A. C. (2013) · Journal of Anatomy · doi:10.1111/joa.12034 · Cited by 66
Yoo, C., Ryu, M., Jo, J., Park, I., Ryoo, B., & Kang, Y. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2015.015 · Cited by 65
Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
Chen, Y., Huang, L., Dong, Y., Tao, C., Zhang, R., Shao, H., & Shen, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.573599 · Cited by 65
Lokker, N. A., O'Hare, J. P., Barsoumian, A., Tomlinson, J. E., Ramakrishnan, V., Fretto, L. J., & Giese, N. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.33037 · Cited by 64
Targeting the hepatocyte growth factor/Met pathway in cancer
Silva, D. M. D., Roy, A., Kato, T., Cecchi, F., Lee, Y. H., Matsumoto, K., & Bottaro, D. P. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160132 · Cited by 64
de Klerk, D. J., Honeywell, R. J., Jansen, G., & Peters, G. J. (2018) · Cancers · doi:10.3390/cancers10120503 · Cited by 64
Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review
Rambhatla, A., Strug, M. R., de Paredes, J. G., Cordoba, M. I., & Thakur, M. (2021) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-021-02181-6 · Cited by 64
Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics
Gucciardo, E., Sugiyama, N., & Lehti, K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1633-0 · Cited by 63
Tworkoski, K., Platt, J. T., Bacchiocchi, A., Bosenberg, M., Boggon, T. J., & Stern, D. F. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12110 · Cited by 63
Giaginis, C., Tsourouflis, G. S., Zizi‐Serbetzoglou, A., Kouraklis, G. P., Chatzopoulou, E., Dimakopoulou, K., & Theocharis, S. E. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-009-9221-6 · Cited by 63
Wang, F., Diao, X., Zhang, X., Shao, Q., Feng, Y., An, X., & Wang, H. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0354-z · Cited by 63
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
Nakamura, I. T., Kohsaka, S., Ikegami, M., Ikeuchi, H., Ueno, T., Li, K., Beyett, T. S., Koyama, T., Shimizu, T., Yamamoto, N., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00204-0 · Cited by 63
Sato, T., Toki, T., Kanezaki, R., Xu, G., Terui, K., Kanegane, H., Miura, M., Adachi, S., Migita, M., Morinaga, S., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07081.x · Cited by 62
Lu, X., Liu, S., Han, M., Yang, X., Sun, K., Wang, H., Mu, H., Du, Y., Wang, A., Ni, L., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.001 · Cited by 62
A structural prospective for collagen receptors such as DDR and their binding of the collagen fibril
Orgel, J. P. R. O., & Madhurapantula, R. S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.04.008 · Cited by 62
Wen, C., Li, Y., Huang, Y., Wang, N., He, S., Bao, M., Zhou, H., & Wu, L. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106344 · Cited by 62
Ouar, Z., Lacave, R., Bens, M., & Vandewalle, A. (1999) · Cell Biology and Toxicology · doi:10.1023/a:1007521430236 · Cited by 61
Zhu, Q., Zhan, P., Zhang, X., Lv, T., & Song, Y. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.05.01 · Cited by 61
VEGFR2 alteration in Alzheimer’s disease
Cho, S.-J., Park, M. H., Han, C., Yoon, K., & Koh, Y. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-18042-1 · Cited by 61
Secondary KIT mutations: the GIST of drug resistance and sensitivity
Napolitano, A., & Vincenzi, B. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0388-7 · Cited by 61
Castro‐Sánchez, L., Soto-Guzmán, A., Guaderrama-Díaz, M., Cortés‐Reynosa, P., & Salazar, E. P. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9385-9 · Cited by 60
Zhou, C., Qian, X., Hu, M., Zhang, R., Liu, N., Huang, Y., Yang, J., Zhang, J., Bai, H., Yang, Y., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1687212 · Cited by 60
Wu, R., Li, K., Yuan, M., & Luo, K. Q. (2021) · Oncogene · doi:10.1038/s41388-021-01691-y · Cited by 60
Fujino, T., Suda, K., Koga, T., Hamada, A., Ohara, S., Chiba, M., Shimoji, M., Takemoto, T., Soh, J., & Mitsudomi, T. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01299-z · Cited by 60
Lhoumeau, A., Martinez, S., Boher, J., Monges, G. M., Castellano, R., Goubard, A., Doremus, M., Poizat, F., Lelong, B., de Chaisemartin, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123768 · Cited by 59
Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands
Zhao, M., Jung, Y., Jiang, Z., & Svensson, K. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00354 · Cited by 59
A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia
Ammar, A. B., Soltanzadeh, P., Bauché, S., Richard, P., Goillot, E., Herbst, R., Gaudon, K., Huzé, C., Schaeffer, L., Yamanashi, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053826 · Cited by 58
Cited by
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Metadata
- Authors
- Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-08-14
- Volume
- 9
- Issue
- 1
- Pages
- 201-201
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4401593620
- Cited by
- 260
- References
- 859
- FWCI
- 68.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.